TLDR:
- Chilean biotechnology company PhageLab has raised $11 million in funding.
- The funding will be used to advance its pipeline of phage-based solutions and establish a commercial position in Brazil.
- PhageLab develops precision bacteriophage treatments to reduce the overuse of antibiotics in the livestock industry.
- The company uses an AI-driven microbial bioinformatics platform to create customized bacteriophage cocktails.
PhageLab, a Chilean biotechnology company, has secured $11 million in funding from investors including Nazca, Collaborative Fund, Water Lemon Ventures, and individual investor Kevin Efrusy. The company plans to use the funds to advance its pipeline of phage-based solutions and establish a commercial position in Brazil, which is its main target market. Additionally, PhageLab intends to expand its technology into the US.
The company was founded in 2010 and focuses on developing precision bacteriophage treatments to reduce the overuse of antibiotics in the livestock industry. PhageLab has created a microbial bioinformatics platform that utilizes artificial intelligence to generate “customized cocktails” of bacteriophages. These cocktails are designed to effectively manage pathogenic bacteria in the livestock industry and reduce dependence on antibiotics. The platform is powered by a training dataset based on more than a decade of experimentation data and tested phage repositories, making it one of the world’s largest industrial bacterial databases.
PhageLab is able to create custom solutions in just 45 days using its library of bacteriophages. The company currently has offices in Spain and Brazil, and the new funding will support its expansion efforts and commercialization strategies.
